机械扩张瓣与自膨胀瓣TAVR两年结局:REPRISE III随机临床试验
REPRISE III试验将912例高危/极高危重度症状性主动脉瓣狭窄患者按2:1随机分配至机械扩张Lotus瓣(607例)或自膨胀CoreValve瓣(305例),随访2年。两组全因死亡及全因死亡或致残性卒中相似,但CoreValve组致残性卒中更高,Lotus组新起搏器植入和瓣膜血栓更多,CoreValve组瓣膜血流动力学更优但瓣周漏更多。
要点
- Lotus与CoreValve两年全因死亡及全因死亡或致残性卒中无显著差异
- Lotus组新起搏器植入(41.7% vs 26.1%)和瓣膜血栓(3.0% vs 0.0%)更多
核心结论
- 两年随访时Lotus与CoreValve的全因死亡、全因死亡或致残性卒中相似。
- 致残性卒中、功能分级改善、瓣膜移位和瓣周漏倾向于Lotus,而瓣膜血流动力学、血栓和新起搏器植入倾向于CoreValve。
研究设计与样本
- REPRISE III是首个大型随机比较两种经导管主动脉瓣置换平台的研究。
- 912例高危/极高危重度症状性主动脉瓣狭窄患者按2:1随机分配至Lotus(607例,66.6%)或CoreValve(305例,33.4%),来自北美、欧洲和澳大利亚55个中心。
临床怎么用
- 对于高危/极高危重度症状性主动脉瓣狭窄患者,两种瓣膜两年生存结局相似,选择需权衡卒中、起搏器、瓣周漏及血流动力学等差异。
- 关注CoreValve组较高的致残性卒中和瓣周漏风险,以及Lotus组较高的新起搏器植入和瓣膜血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To our knowledge, REPRISE III is the first large randomized comparison of 2 different transcatheter aortic valve replacement platforms: the mechanically expanded Lotus valve (Boston Scientific) and self-expanding CoreValve (Medtronic). OBJECTIVE: To evaluate outcomes of Lotus vs CoreValve after 2 years. DESIGN, SETTING, AND PARTICIPANTS: A total of 912 patients with high/extreme risk and severe, symptomatic aortic stenosis enrolled between September 22, 2014, and December 24, 2015, were randomized 2:1 to receive Lotus (607 [66.6%]) or CoreValve (305 [33.4%] at 55 centers in North America, Europe, and Australia. The first 2-year visit occurred on October 17, 2016, and the last was conducted on April 12, 2018. Clinical and echocardiographic assessments are complete through 2 years and will continue annually through 5 years. MAIN OUTCOMES AND MEASURES: All-cause mortality and all-cause mortality or disabling stroke at 2 years. Other clinical factors included overall stroke, disabling stroke, repeated procedures, rehospitalization, valve thrombosis, and pacemaker implantation. Echocardiographic analyses included effective orifice area, mean gradient, and paravalvular leaks (PVLs). RESULTS: Of 912 participants, the mean (SD) age was 82.8 (7.3) years, 465 (51%) were women, and the mean (SD) Society of Thoracic Surgeons predicted risk of mortality was 6.8% (4.0%). At 2 years, all-cause death was 21.3% with Lotus vs 22.5% with CoreValve (hazard ratio [HR], 0.94; 95% CI, 0.69-1.26; P = .67) and all-cause mortality or disabling stroke was 22.8% with Lotus and 27.0% with CoreValve (HR, 0.81; 95% CI, 0.61-1.07; P = .14). Overall stroke was 8.4% vs 11.4% (HR, 0.75; 95% CI, 0.48-1.17; P = .21); disabling stroke was more frequent with CoreValve vs Lotus (4.7% Lotus vs 8.6% CoreValve; HR, 0.53; 95% CI, 0.31-0.93; P = .02). More Lotus patients received a new permanent pacemaker (41.7% vs 26.1%; HR, 1.87; 95% CI, 1.41-2.49; P < .01) or had a valve thrombosis (3.0% vs 0.0%; P < .01) compared with CoreValve. More patients who received CoreValve experienced a repeated procedure (0.6% Lotus vs 2.9% CoreValve; HR, 0.19; 95% CI, 0.05-0.70; P < .01), valve migration (0.0% vs 0.7%; P = .05), or embolization (0.0% vs 2.0%; P < .01) than Lotus. Valve areas remained significantly larger and the mean gradient was lower with CoreValve than Lotus (valve area, mean [SD]: Lotus, 1.53 [0.49] cm2 vs CoreValve, 1.76 [0.51] cm2; P < .01; valve gradient, mean [SD]: Lotus, 13.0 [6.7] mm Hg vs 8.1 [3.7] mm Hg; P < .01). Moderate or greater PVL was more frequent with CoreValve (0.3% Lotus vs 3.8% CoreValve; P < .01) at 2 years. Larger improvements in New York Heart Association (NYHA) functional class were observed with Lotus compared with CoreValve (improved by ≥1 NYHA class: Lotus, 338 of 402 [84.1%] vs CoreValve, 143 of 189 [75.7%]; P = .01; improved by ≥2 NYHA classes: 122 of 402 [37.3%] vs 65 of 305 [21.3%]). CONCLUSIONS AND RELEVANCE: After 2 years, all-cause mortality rates, mortality or disabling stroke were similar between Lotus and CoreValve. Disabling stroke, functional class, valve migration, and PVL favored the Lotus arm whereas valve hemodynamics, thrombosis, and new pacemaker implantation favored the CoreValve arm. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02202434.
引用
- Reardon MJ, Feldman TE, Meduri CU, et al. Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanical vs Self-expanding Valves: The REPRISE III Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 30810703. doi:10.1001/jamacardio.2019.0091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。